Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S

Group 1 - Genmab A/S is recognized as a global leader in antibody-based therapies, with significant commercial successes and advancements in late-stage clinical trials in 2025 [1][4] - The company markets therapies such as Tivdak for cervical cancer and Epkinly for lymphoma, while also developing a strong pipeline focused on high-need oncology indications [1][4] - A notable achievement for Genmab this year is the FDA's Breakthrough Therapy Designation for rinatabart sesutecan (Rina-S), which is aimed at treating recurrent or progressive endometrial cancer [2][4] Group 2 - Genmab's bispecific antibody epcoritamab shows promising results as an outpatient therapy for diffuse large B-cell lymphoma (DLBCL), with 92% of patients able to receive their first full dose in an outpatient setting [3] - The company is expanding the global reach of its marketed therapies, Tivdak and Epkinly, while utilizing its KYSO antibody platform to enhance its pipeline [4]